Boekhorst Paul Francis Olivier te

CIK: 0002095704

Transaction Breakdown

Open Market Buys (P)6 (66.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ICCC

IMMUCELL CORP /DE/

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

ICCC
IMMUCELL CORP /DE/
Jun 18, 2026
Purchase(P)
Direct
8K shares at avg. $9.49$76K
ICCC
IMMUCELL CORP /DE/
Jan 27, 2026
Award(A)
Stock Options (right to buy)
Direct
109.5K shares-
ICCC
IMMUCELL CORP /DE/
Jan 27, 2026
Award(A)
Stock Options (right to buy)
Direct
110K shares-
ICCC
IMMUCELL CORP /DE/
Dec 4, 2025
Purchase(P)
Direct
2.4K shares at avg. $5.50$13K
ICCC
IMMUCELL CORP /DE/
Dec 3, 2025
Purchase(P)
Direct
3.6K shares at avg. $5.04$18K
ICCC
IMMUCELL CORP /DE/
Dec 3, 2025
Purchase(P)
Direct
3.5K shares at avg. $5.04$18K
ICCC
IMMUCELL CORP /DE/
Dec 3, 2025
Purchase(P)
Direct
2.6K shares at avg. $5.00$13K
ICCC
IMMUCELL CORP /DE/
Dec 2, 2025
Purchase(P)
Direct
3.7K shares at avg. $4.87$18K
ICCC
IMMUCELL CORP /DE/
Nov 7, 2025
Award(A)
Stock Options (right to buy)
Direct
74.3K shares at avg. $6.10-

		Type	Shares	Price		Ownership
Jun 18, 2026	ICCC IMMUCELL CORP /DE/	Purchase(P)	8,000	$9.49	$75,960	Direct
Jan 27, 2026	ICCC IMMUCELL CORP /DE/	Award(A) Stock Options (right to buy)	109,500	-	-	Direct
Jan 27, 2026	ICCC IMMUCELL CORP /DE/	Award(A) Stock Options (right to buy)	110,000	-	-	Direct
Dec 4, 2025	ICCC IMMUCELL CORP /DE/	Purchase(P)	2,432	$5.50	$13,376	Direct
Dec 3, 2025	ICCC IMMUCELL CORP /DE/	Purchase(P)	3,598	$5.04	$18,152	Direct
Dec 3, 2025	ICCC IMMUCELL CORP /DE/	Purchase(P)	3,521	$5.04	$17,748	Direct
Dec 3, 2025	ICCC IMMUCELL CORP /DE/	Purchase(P)	2,556	$5.00	$12,788	Direct
Dec 2, 2025	ICCC IMMUCELL CORP /DE/	Purchase(P)	3,708	$4.87	$18,053	Direct
Nov 7, 2025	ICCC IMMUCELL CORP /DE/	Award(A) Stock Options (right to buy)	74,277	$6.10	-	Direct

1-9 of 9 transactions

About te Boekhorst Paul Francis Olivier

te Boekhorst Paul Francis Olivier (SEC CIK 0002095704) files insider reports with the SEC as President and CEO of IMMUCELL CORP /DE/ (ICCC).

Signal8 holds 7 ownership filings by te Boekhorst Paul Francis Olivier (1 Form 3, 6 Form 4), filed between Nov 7, 2025 and Jun 22, 2026. Those filings report 9 transactions, from Nov 7, 2025 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on te Boekhorst Paul Francis Olivier's filings is in PORTLAND, ME.

Recent filings by te Boekhorst Paul Francis Olivier

Jun 18, 2026: Open-market purchase of ICCC shares (Form 4, code P).
Jan 27, 2026: Grants or awards of ICCC derivative securities (2 lines, Form 4, code A).
Dec 4, 2025: Open-market purchase of ICCC shares (Form 4, code P).
Dec 3, 2025: Open-market purchases of ICCC shares (3 lines, Form 4, code P).
Dec 2, 2025: Open-market purchase of ICCC shares (Form 4, code P).

Other insiders filing for IMMUCELL CORP /DE/ (ICCC)

DiMarco Anthony, Director
Guillemette Gilles, Director
Turner Kathy V, Director
Tomsche David Scott, Director
Basse Gloria F, Director
Wainman Paul R, Director

How to read Form 4 transaction codes